Most nasal lymphomas in these populations are of NK-cell lineage ... The role of autologous and allogeneic hematopoietic stem-cell transplantation should be established by controlled trials.

While it’s also possible to make an autologous patient-specific therapy from NK cells, Shingleton doesn’t see that idea taking off. “Beating the efficacy of CAR-T would be tough,” he says.

More information: Costin Tomescu et al, Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4+ T cells by ADCC, The Journal of ...

Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative ...

(“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell ...

With a bone marrow transplant, the stem cells are taken from the bone marrow. With a stem cell transplant, the stem cells are taken from either the bone marrow or the bloodstream. There are 2 main ...

NKGen Biotech (NKGN) announced the oral presentation of updated Phase 1 clinical data from the Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy ...

Radiologic imaging of the primary tumor is an essential initial evaluation. CT scans detect bony involvement well, but soft tissue infiltration is much better defined with MRI. Nasal lymphomas ...

March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen” or the "Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative ...

Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative ...